INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,977,294 | -11.7% | 4,280,308 | +17.1% | 1.13% | -15.0% |
| Q2 2023 | $20,360,066 | -2.8% | 3,655,308 | 0.0% | 1.33% | -0.4% |
| Q1 2023 | $20,944,915 | +445.7% | 3,655,308 | 0.0% | 1.34% | +487.7% |
| Q4 2022 | $3,838,073 | -60.8% | 3,655,308 | 0.0% | 0.23% | -60.0% |
| Q3 2022 | $9,796,000 | -43.8% | 3,655,308 | 0.0% | 0.57% | -60.7% |
| Q2 2022 | $17,436,000 | +110.2% | 3,655,308 | +80.2% | 1.45% | +130.5% |
| Q1 2022 | $8,296,000 | -40.0% | 2,028,308 | 0.0% | 0.63% | -22.0% |
| Q4 2021 | $13,833,000 | -41.2% | 2,028,308 | 0.0% | 0.81% | -42.0% |
| Q3 2021 | $23,508,000 | -32.0% | 2,028,308 | 0.0% | 1.39% | -30.1% |
| Q2 2021 | $34,562,000 | -13.9% | 2,028,308 | 0.0% | 1.99% | -17.5% |
| Q1 2021 | $40,160,000 | -4.1% | 2,028,308 | 0.0% | 2.41% | -3.1% |
| Q4 2020 | $41,864,000 | -21.5% | 2,028,308 | 0.0% | 2.49% | -37.0% |
| Q3 2020 | $53,324,000 | – | 2,028,308 | – | 3.95% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |